Table 2.

Subgroup analysis results of Total glucosides of paeony.

Outcomes	Subgroup	Overall effect			Heterogeneity test		Statistical method	Studies (N)	Sample size (N)	Figure
		Effect	95%CI	P	I2 (%)	P(Q)
DAS28	12 weeks	WMD=-0.80	[-1.68, 0.07]	0.07	93.09	<0.001	Random	5	670	Figure S1
	24 weeks	WMD=-1.06	[-2.51, 0.39]	0.15	98.00	<0.001	Random	2	314
	≥36 weeks	WMD=-1.03	[-2.73, 0.66]	0.23	96.61	<0.001	Random	2	162
ESR	≤12 weeks	WMD=-6.53	[-9.92, -3.13]	<0.001	87.17	<0.001	Random	11	1018	Figure S2
	24 weeks	WMD=-5.57	[-14.50, 3.37]	0.22	81.66	<0.001	Random	4	424
	36 weeks	WMD=-5.80	[-9.59, -2.01]	<0.001	–	–	Random	1	80
CRP	≤12 weeks	SMD=-1.44	[-2.14, -0.73]	<0.001	95.90	<0.001	Random	11	1001	Figure S3
	24 weeks	SMD=-1.23	[-2.13, -0.33]	<0.001	92.98	<0.001	Random	4	350
	≥36 weeks	SMD=-1.00	[-1.33, -0.67]	0.00	0.00	0.42	Random	2	162
RF	≤12 weeks	SMD=-1.20	[-1.89, -0.50]	<0.001	94.23	<0.001	Random	7	700	Figure S4
	≥ 24 weeks	SMD=-5.26	[-9.62, -0.89]	0.02	99.26	<0.001	Random	3	284
Adverse events	≤12 weeks	RR=0.56	[0.42, 0.77]	<0.001	0.00	0.86	Random	9	852	Figure S5
	≥24 weeks	RR=0.53	[0.37, 0.76]	<0.001	0.00	0.95	Random	6	510
DAS28	Twice a day	WMD=-1.8	[-2.08, -1.52]	0.00	–	–	Random	1	120	Figure S6
	Three times a day	WMD=-0.80	[-1.38, -0.21]	<0.001	92.85	<0.001	Random	8	1026
ESR	Twice a day	WMD=-13.54	[-19.32, -7.77]	<0.001	86.33	0.00684	Random	2	200	Figure S7
	Three times a day	WMD=-5.13	[-7.67, -2.58]	<0.001	67.79	0.000121	Random	14	1322
CRP	Twice a day	SMD=-3.67	[-5.56, -1.77]	<0.001	96.50	<0.001	Random	3	320	Figure S8
	Three times a day	SMD=-0.87	[-1.23, -0.50]	<0.001	88.58	<0.001	Random	14	1193
RF	Twice a day	SMD=-7.15	[-11.07, -3.23]	<0.001	98.79	<0.001	Random	3	320	Figure S9
	Three times a day	SMD=-0.40	[-0.94, 0.15]	0.15	91.30	<0.001	Random	7	664
Adverse events	Twice a day	RR=0.48	[0.28, 0.81]	<0.001	0.00	0.80	Random	3	280	Figure S10
	Three times a day	RR=0.57	[0.44, 0.74]	<0.001	0.00	0.96	Random	12	1082